Community-acquired pneumonia in hospitalised patients: changes in aetiology, clinical presentation, and severity outcomes in a 10-year period

Júlia Sellarès-Nadal a,b,c, Joaquín Burgos a,b,c, María Teresa Martín-Gómez d, Andrés Antón d, Roger Sorde e, Daniel Romero-Herrero a,b, Pau Bosch-Nicolau a,b, Anna Falco-Roget a,b, Cristina Kirkegaard a,b, Dolors Rodríguez-Pardo b, and Vicenç Falco a,b,c

aDepartament de Medecina, Universitat Autònoma de Barcelona, Bellaterra, Spain; bInfectious Diseases Department, Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain; cMalalties Infeccioses Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain; dMicrobiology Department, Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain; eInternal Medicine Department, Hospital de Trauma Manuel Giagni, Ministerio de Salud Pública y Bienestar Social, Asunción, Paraguay

ABSTRACT

Background and objective: Community-acquired pneumonia (CAP) is a frequent cause of hospitalisation. Several factors, such as pandemics, vaccines and globalisation may lead to changes in epidemiology, clinical presentation, and outcomes of CAP, which oblige to a constant actualisation. We performed this study to analyse how these factors have evolved over a 10-year period.

Materials and methods: Patients diagnosed with CAP for two 1-year periods that were 10 years apart (2007–2008 and 2017–2018) were included. We compared microbiological information, clinical data and evolutive outcomes in the two periods. A mortality analysis was performed.

Results: 1043 patients were included: 452 during the first period (2007–2008), and 591 during the second period (2017–2018). Bacterial aetiology did not change during the 10-year period, besides a slight increase in Staphylococcus aureus (0.9% vs 2.9%, p = 0.026). There was a decline in the proportion of bacteraemia in the second period (14.8% vs 9.6%, p = 0.012). The incidence of complicated pleural effusion and septic shock declined too (6.4% vs 3.6%, p = 0.04 and 15.5% vs 6.3%, p < 0.001). Respiratory failure and Intensive care unit (ICU) admission were similar in both periods. Variables independently associated with mortality were age and septic shock. Influenza vaccine was a protective factor against mortality in the second period.

Conclusions: We have not found relevant differences in the bacterial aetiology of CAP over this 10-year period. There has been a decline in septic complications of CAP such as septic shock, bacteraemia, and complicated pleural effusion. Influenza vaccination is an important tool to reduce mortality.

KEY MESSAGES

• There were no differences in the bacterial pathogens causing CAP among the 10-year study period. There has been a decline in septic complications of CAP such as septic shock, bacteraemia, and complicated pleural effusion.

Introduction

Community-acquired pneumonia (CAP) is one of the main challenges in infectious diseases, as it represents an important cause of morbidity and mortality, and it is a frequent cause of hospitalisation worldwide [1–3]. Moreover, infectious diseases are a dynamic field, in which epidemiology is constantly evolving. Changes in environmental factors, the introduction of new vaccines and globalisation itself may lead to changes in epidemiology, clinical presentation, and severity of CAP. Therefore, periodic survey studies are needed to ensure that clinical guidelines remain adequate [4,5].

With the development of new diagnostic methods such as molecular testing, there has been an improvement in the identification of etiologic causes of CAP [6,7]. This has led to an increase of viral detection in patients with CAP, reaching up to 24.5–30% of all cases [8,9]. Some bacteria, such as Staphylococcus aureus, have traditionally been related to viral co-infection. Recent guidelines recommend the investigation
of respiratory viruses mainly during the flu-season [4], however, the impact on bacterial aetiology and clinical outcomes of patients has been barely evaluated. With such diagnostic approach, we wonder if there has been changes in the pathogens detected and in the outcomes of patients with CAP in the last years.

Another relevant change affecting the management of respiratory-tract infections in the latest years is the expansion of vaccination programs with higher vaccination targets [10]. On the one hand, it is known that influenza vaccine reduces the rates of influenza infection as well as improves the prognosis of patients [11]. On the other hand, in our setting the 13-valent conjugate pneumococcal vaccine was introduced in 2010, and there is little information on its impact on clinical presentation and severity outcomes of adult patients with CAP [12]. We wonder if vaccination policies have had an impact on the severity and outcomes of patients with CAP in the last decade.

We designed this study to analyse if there have been changes in the epidemiology, clinical presentation, and outcomes of CAP over a 10-year period. We included patients diagnosed with CAP for two 1-year periods that were 10 years apart (2007–2008 and 2017–2018). Between these 2 periods detection of respiratory virus, mainly during the flu season, was implemented in our hospital. The objectives of the study were to study if there have been changes in the clinical presentation, bacterial aetiology, and outcomes of patients with CAP between these two periods.

**Materials and methods**

**Study design and inclusion criteria**

This is an observational study of all consecutive adult inpatients (age ≥18 years) diagnosed with CAP in two periods separated by 10 years: 2007–2008 and 2017–2018. The study was conducted at the Hospital Universitari Vall d’Hebron, a 1100 beds-tertiary teaching hospital in Barcelona. Patients with nosocomial pneumonia and those with evidence of aspiration pneumonia (dysphagia, altered gag reflex, low level of consciousness) were excluded.

**Data collection**

We collected epidemiologic information (age, sex, residency in nursing home, smoking, alcohol consumption and vaccination status), comorbidities (hypertension, chronic obstructive pulmonary disease (COPD), diabetes mellitus, chronic renal failure, neurological disorders, and neoplasms) and immunosuppressive factors (solid organ transplantation, haematopoietic transplantation, chemotherapy, long-term use of corticosteroids, and HIV infection). We also registered clinical information, laboratory results, radiological findings, microbiological information, and severity data (septic shock and respiratory failure). Empiric treatment was recorded. Evolutive variables, such as admission at the Intensive Care Unit (ICU) and in-hospital mortality were collected. CURB-65 score and Pneumonia Severity Index (PSI) were calculated.

**Microbiologic procedures**

Microbiologic diagnostic procedures were performed according to the hospital protocol and included (1) two sets of blood cultures, (2) when available, qualitative and semi-quantitative culture of a good quality sputum sample as previously defined [13], (3) in patients who required oro-tracheal intubation, an endotracheal aspirate or bronco-alveolar-lavage samples (4), urinary antigen for Streptococcus pneumoniae in all patients, (5) urinary antigen for Legionella pneumophila if there was clinical or epidemiological suspicion and in all cases of severe CAP. Other microbiological techniques such as PCR for S. pneumoniae in pleural fluid or serologic determinations for antibodies against atypical pathogens were performed according to clinical or epidemiological suspicion. We considered a positive sputum culture when the semi-quantitative culture yielded > 1.000.000 colony-forming units (CFU) or when the microorganism was found to be predominant in qualitative cultures.

The only difference in the microbiologic procedures performed in the two periods was viral detection. In the second period (2017–2018) a multiplex real-time PCR determination of respiratory virus (Influenza A and B, including Flu A-H1pdm09, Respiratory Syncytial Virus A and B, Adenovirus, Enterovirus, Metapneumovirus, Parainfluenza 1–4 Virus, Rhinovirus, Bocavirus 1–4, and Coronavirus NL63, OC43 and 229E) in a nasopharyngeal swab was performed if requested by the attending physician in case of clinical or epidemiological suspicion (Allplex™ Respiratory Panels 1, 2 and 3, Seegene Inc., Korea). During the flu season (from November 2017 to March 2018) a rapid narrow-range real-time PCR for influenza virus was also performed (Xpert Flu/RSV™, Cepheid, Sunnyvale, CA, USA).

**Definitions**

Pneumonia was defined as the presence of signs or symptoms of respiratory-tract infection (cough, fever,
purulent sputum, pleuritic chest pain or pulmonary semiology compatible with lung consolidation) associated with the presence of a newly visualised infiltrate in the chest radiography.

Bacterial pneumonia was diagnosed in patients when (1) a microorganism likely to cause bacterial pneumonia was isolated in blood, pleural fluid, acceptable-quality sputum, endotracheal aspirate or broncho-alveolar-lavage samples, (2) a PCR for *S. pneumoniae* was positive in pleural fluid, (3) a urinary antigen test for *S. pneumoniae* or *L. pneumophila* was positive, (4) seroconversion of *L. pneumophila, M. pneumoniae, C. pneumoniae, C. psittaci* and *C. burnetii* antibody titres was documented. Viral infection was considered in all patients presenting a positive real PCR test for respiratory virus, regardless of the detection of a bacterial microorganism. Respiratory failure was defined as pO2 in arterial blood lower or equal to 60 mmHg or peripheral pulse oximetry lower than 90%. Septic shock was defined as the need of vasopressors to maintain medium blood pressure over 65 mmHg despite an adequate volume status.

**Treatment**

Patients received antibiotic treatment according to current local protocols, which did not change between the two study periods. Hospitalised patients with non-severe CAP received amoxicillin-clavulanic acid and in those with severe CAP, a third-generation cephalosporin (ceftriaxone or cefotaxime) associated with a macrolide (azithromycin) was prescribed. Fluoroquinolones were recommended in cases of penicillin allergy or as an alternative treatment at the attending physician discretion when there was a clinical suspicion for atypical pneumonia. In the second period, a 5-day course of oseltamivir was recommended for inpatients with confirmed influenza infection.

**Statistical analysis**

We performed a descriptive analysis of basal characteristics, clinical and microbiological information of the study population. Categorical variables are expressed as percentages and numerical data as mean and standard deviation (SD) in cases of normal distribution or as median and interquartile range (IQR) for nonnormally distributed data. Variables were compared between the two periods using the Chi-square test for qualitative variables and T-student test for quantitative variables. We performed first a multivariate analysis (forward onwards) by binary logistic regression to identify variables independently associated with mortality. Secondly, we performed a multivariate analysis of mortality in each period in order to know the evolution of risk factors in both periods. Significant (*p < 0.05*) variables from the univariate analysis were included in the multivariate analysis. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY; IBM Corp. Released 2011.

**Ethics statement**

The study was approved by the Ethics Committee of Vall d’Hebron Research Institute (registration code PR(AG)345/2018). Need for informed consent was waived, as data and samples were analysed retrospectively, and the study was non-interventional in nature.

**Results**

Overall, 1043 patients were included: 452 during the first period (2007–2008) and 591 during the second period (2017–2018). Monthly distribution of cases was similar in both periods (Figure 1). Six hundred and sixty-two (63.5) were men, and the mean age was 65 years (SD 18.8). In Table 1, we present the demographic characteristics and comorbid conditions of the study population. In the second period, patients were slightly older (63.4 ± 66.1 years; *p = 0.02*) and there was a higher proportion of women (33% vs. 39.3%; *p = 0.038*). The proportion of patients with any underlying condition was similar, despite there were some differences in the type of comorbidities. A higher proportion of patients were vaccinated against influenza during the flu season in the second period.

Table 2 shows the pathogens documented in both periods. Bacterial aetiology did not change over the 10-years period. The only difference observed was a slight but significant increase in *S. aureus* CAP in the second period (*p = 0.026*). Methicillin-resistant *S. aureus* (MRSA) represented 1 out of 4 *S. aureus* isolates in the first period and 4 out of 13 in the second period (25% vs 23.5%, *p = 1.0*). There was a decline in the proportion of bacteraemic CAP in the second period (14.8% vs 9.6%, *p = 0.012*).

Regarding severity and clinical presentation, CURB-65 and PSI scores were similar in both periods (Table 3). The incidence of septic complications (complicated pleural effusion and septic shock) declined in the second period (6.4% vs 3.6%, *p = 0.004* and 15.5% vs 5.3%, *p < 0.001*, respectively). On the other hand,
respiratory failure and ICU admission were similar in both periods. During the second period, hospitalisation length was shorter than in the first period.

Regarding mortality, although there were no significant differences between the two periods, there was a slight trend to lower 30-day mortality in the second period (8.8% vs 5.8%, \( p = 0.067 \)). In the multivariate analysis, the independent factors associated with mortality were age (OR 1.05; 95%CI 1.3–1.7), septic shock (OR 5.38; 95%CI 3.00–9.67) and respiratory failure (OR 3.97; 95%CI 2.14–7.35). In order to know the variables associated with mortality in each period we performed a mortality analysis in each period which is shown in Table 4. Age and septic shock were variables independently associated with mortality in both periods. Respiratory failure was a risk factor but only in the first period (OR 7.57; 95%CI 2.83–20.2). Finally, we observed that in the second period, in which the rate of influenza vaccination was significantly higher (Table 1), influenza vaccination was an independent protective factor against mortality (OR 0.15; 95%CI 0.05–0.44).

**Discussion**

The epidemics and the bacterial aetiology of CAP did not suffer a relevant clinical change along a 10-year period. Bacterial pathogens did not differ over the years, although there was a slight but significant increase in the presence of *S. aureus* during the second period. During that period, the prevalence of
Table 2. Viral and bacterial pathogens documented in both periods.

| Pathogen                        | Total, n = 1043 (%) | 2007–2008, n = 452 (%) | 2017–2018, n = 591 (%) | p    |
|---------------------------------|---------------------|------------------------|------------------------|------|
| **Bacteria documented**         |                     |                        |                        |      |
| Streptococcus pneumoniae        | 382 (36.6)          | 171 (37.8)             | 211 (35.7)             | 0.517|
| Staphylococcus aureus           | 21 (2.0)            | 4 (0.9)                | 17 (2.9)               | 0.026|
| Legionella pneumophila          | 31 (3.0)            | 15 (3.3)               | 16 (2.7)               | 0.585|
| Other atypical bacteria         | 15 (1.4)            | 7 (1.5)                | 8 (1.4)                | 0.799|
| Haemophilus influenzae          | 28 (2.7)            | 13 (2.9)               | 15 (2.5)               | 0.847|
| *Pseudomonas aeruginosa*        | 17 (1.6)            | 11 (2.4)               | 6 (1.0)                | 0.086|
| Other bacteria                  | 36 (3.5)            | 16 (3.5)               | 20 (3.4)               | 1.00 |
| More than one bacteria          | 39 (3.7)            | 10 (2.2)               | 29 (4.9)               | 0.031|
| No bacteria detected            | 474 (45.4)          | 205 (45.4)             | 269 (45.5)             | 1.00 |
| **Virus documented**            |                     |                        |                        |      |
| Influenza A                     |                     |                        |                        |      |
| Influenza B                     | –                   | –                      | 31 (5.2)               |      |
| Respiratory syncytial virus     | –                   | –                      | 16 (2.7)               |      |
| Rhinovirus                      | –                   | –                      | 20 (3.4)               |      |
| Adenovirus                      | –                   | –                      | 3 (0.5)                |      |
| Coronavirus (not SARS-CoV2)     | –                   | –                      | 9 (1.5)                |      |
| Metapneumovirus                 | –                   | –                      | 5 (0.8)                |      |
| Parainfluenza virus             | –                   | –                      | 1 (0.2)                |      |
| Any bacterial or viral pathogen | 623 (59.7)          | 247 (54.6)             | 376 (63.6)             | 0.004|
| Positive blood cultures         | 124 (11.9)          | 67 (14.8)              | 57 (9.6)               | 0.12 |

Table 3. Clinical information of CAP in the two periods.

|                                      | Total, n = 1043 (%) | 2007–2008, n = 452 (%) | 2017–2018, n = 591 (%) | p    |
|--------------------------------------|---------------------|------------------------|------------------------|------|
| **Bilateral consolidation**          |                     |                        |                        |      |
| Complicated pleural effusiona        | 131 (12.6)          | 59 (13.1)              | 72 (12.2)              | 0.706|
| Severity scores                      |                     |                        |                        |      |
| PSI high mortality classes (IV or V) | 580 (55.7)          | 255 (56.7)             | 325 (55)               | 0.615|
| CURB-65 high mortality risk group (≥3 points) | 238 (22.8) | 92 (20.4) | 146 (24.7) | 0.102|
| ICU admission                        | 94 (9.0)            | 41 (9.1)               | 53 (9.0)               | 1.00 |
| Septic shock                         | 107 (10.3)          | 70 (15.5)              | 37 (6.3)               | <0.001|
| Respiratory failure                  | 454 (43.5)          | 196 (43.4)             | 258 (43.7)             | 0.95 |
| Invasive mechanical ventilation      | 54 (5.2)            | 30 (6.6)               | 24 (4.1)               | 0.068|
| Mean of hospitalisation days (SD)    | 10.2 (12.9)         | 11.9 (14.0)            | 8.9 (11.8)             | <0.001|
| Mortality                            |                     |                        |                        |      |
| Mortality during hospitalisation     | 83 (8.0)            | 41 (9.1)               | 42 (7.1)               | 0.251|
| 48-h mortality                      | 26 (2.5)            | 11 (2.4)               | 15 (2.5)               | 1.00 |
| 30-day mortality                    | 74 (7.1)            | 40 (8.8)               | 34 (5.8)               | 0.067|

Data are expressed as numbers and percentages unless otherwise indicated. ICU: intensive care unit, SD: standard deviation, PSI: pneumonia severity index. *Complicated pleural effusion: pH < 7.2, low glucose levels or evidence of microorganism by culture or gram stain. *Septic shock: need of vasoactive drugs. *Respiratory failure: pO2 in arterial blood lower or equal to 60 mmHg or peripheral pulse-oximetry lower than 90%.

Table 4. 30-Day mortality analysis (univariate and multivariate) in the two periods.

|                                      | Univariate analysis | Multivariate analysis |
|--------------------------------------|---------------------|-----------------------|
|                                      | Alive at 30 days, n = 412 (%) | Death at 30 days, n = 40 (%) | p    | Odds ratio (95% CI) | p    |
| First period (2007–2008)             |                     |                        |      |                    |      |
| Mean (SD) age (years)                | 62.2 (19.7)         | 73.4 (15.2)            | 0.001| 1.037 (1.01–1.06)  | 0.002|
| Nursing home                         | 15 (3.6)            | 6 (15)                 | 0.007| –                    | –     |
| Any underlying condition             | 222 (53.9)          | 28 (70)                | 0.066| –                    | –     |
| Influenza vaccination                 | 71 (17.2)           | 5 (12.5)               | 0.657| –                    | –     |
| Bilateral consolidation              | 110 (11.4)          | 21 (28.4)              | <0.001| –                    | –     |
| Respiratory failure                  | 161 (39.1)          | 35 (87.5)              | <0.001| 7.571 (2.83–20.2)  | <0.001|
| Septic shock                         | 53 (12.9)           | 17 (42.5)              | <0.001| 3.755 (1.74–8.02)  | 0.001|
| Positive blood cultures              | 56 (13.6)           | 11 (27.5)              | 0.032| –                    | –     |

|                                      | Alive at 30 days, n = 557 (%) | Death at 30 days, n = 34 (%) | p    | Odds ratio (95% CI) | p    |
|                                      |                     |                        |      |                    |      |
| Second period (2017–2018)            |                     |                        |      |                    |      |
| Mean (SD) age (years)                | 65.3 (18.2)         | 79 (10.8)               | <0.001| 1.092 (1.05–1.13)  | <0.001|
| Nursing home                         | 29 (5.2)            | 5 (17.6)                | 0.001| –                    | –     |
| Any underlying condition             | 298 (53.5)          | 7 (28.2)                | 0.001| –                    | –     |
| Influenza vaccination                 | 183 (32.9)          | 4 (11.8)                | 0.012| 0.146 (0.049–0.436) | 0.001|
| Bilateral consolidation              | 60 (10.8)           | 12 (35.3)               | <0.001| –                    | –     |
| Respiratory failure                  | 233 (41.8)          | 25 (73.5)               | 0.001| 8.676 (3.3–22.83)  | <0.001|
| Septic shock                         | 28 (5.0)            | 9 (26.5)                | <0.001| –                    | –     |
| Positive blood cultures              | 49 (8.8)            | 8 (23.5)                | 0.011| –                    | –     |

SD: Standard deviation, CI: confidence interval. Septic shock: need of vasoactive drugs; Respiratory failure: pO2 in arterial blood lower or equal to 60 mmHg or peripheral pulse-oximetry lower than 90%.
S. aureus CAP was 2.9% which is similar to that reported in other studies [2]. *Staphylococcus aureus* has classically been related with influenza infection and several studies have demonstrated an increase in *S. aureus* detection during the flu-season [2,14]. Microbiological procedures did not differ between the two periods except for the determination of respiratory viruses, which was implemented in the second period. Therefore, we do not have epidemiological data on viral infection during the first period and it is not possible to concrete if the slight increase in *S. aureus* detection in the second could be explained by a rise in influenza virus infections.

In the era of antibiotic resistance, antibiotic susceptibility should constantly be assessed. Studies performed in other settings show a high proportion of MRSA, reaching 40–60% of all *S. aureus* isolates [14,15]. In our study, CAP caused by MRSA represents less than 0.5%, with no changes between the two periods. Considering the stability in the proportion of MRSA detection, we consider that empirical treatment should not be modified to offer MRSA coverage in our setting.

Concerning clinical and severity outcomes, despite the population in both periods had similar rates of underlying conditions and initial severity scores (CURB-65 and PSI), in the second period there was a decline of septic complications such as septic shock and complicated pleural effusion. The proportion of patients with positive blood-cultures decreased as well. These results go in the opposite direction than previous studies, in which an increase of septic complications over the years was reported [12,16]. Pneumococcal serotypes may be related with these changes since they are one of the determinants of severity in patients with pneumococcal disease and therefore in patients with CAP. Over the years, changes in the serotype prevalence have led to changes in the clinical presentation and severity of subjects with CAP. The implementation of the 7-valent vaccine brought a decline in the number of hospitalisations for pneumococcal disease in children and adults [17]. Despite this, in the years after its implementation, concerns raised regarding the increase of non-vaccine serotypes [16,18,19] which came along with an increase of suppurated complications such as empyema [20,21]. In our study, between the two study periods, 13-valent conjugate pneumococcal vaccine was implemented, which could explain the changes mentioned above. Clinical changes after the introduction of the 13-valent vaccine have barely been reported. Simonetti et al assessed clinical outcomes 3 years after its introduction and reported stability in the rates of septic shock in 2010–2014 [12]. In comparison, in our study we have observed a decrease in septic complications in the second period, which could be explained by changes in the population pattern of serotypes in adults due to the implementation of the 13-valent vaccine in children. Further studies with pneumococcal serotype determinations are needed to make more concise statements on this subject.

Finally, in the mortality analysis we found that factors independently associated with 30-day mortality were age and septic shock. These findings are expected since they represent risk factors for mortality in other diseases as well [22,23], and this fact has not changed in the 10-year period.

Interestingly, influenza vaccination was a protective factor against mortality in the second period, in which vaccination rates were significantly higher than in the first period. With the increase in vaccination rates, influenza vaccine became a protective factor of mortality. It is known that an increase in the population vaccination rates can imply a herd effect and promote community protection [24]. Our results are concordant with other studies in which influenza vaccine is a protective factor against in-hospital death [25]. Therefore, we support that influenza vaccination is an important tool to prevent mortality in patients with CAP.

Our study has some limitations. First, the retrospective nature of the study entails design limitations. Second, it presents data from only one centre, so it might not be representative of other geographical areas, where some factors could differ. Third, the study was performed before the emergence of the SARS-CoV-2 pandemic, so we have not addressed the interaction between bacterial pneumonia and SARS-CoV-2 infection. However, in contrast to what occurs in patients with severe influenza in which bacterial co-pathogens are commonly identified, the overall proportion of bacterial coinfection among patients with COVID-19 seems to be only 6.9–8% [26,27]. Finally, we do not have data on pneumococcal serotypes in patients with pneumococcal pneumonia so we cannot make concise statements on the effect of pneumococcal vaccination in the decrease of septic complications.

**Conclusion**

We have not found relevant differences in the bacterial aetiology of CAP over this 10-year period besides a slight increase in *S. aureus* infections. Moreover, there has been a decline in septic complications of CAP such as septic shock, bacteraemia, and complicated
pleural effusion. Influenza vaccination is an important strategy to decrease mortality in patients with CAP. Therefore, in our opinion, the current management for patients with CAP stated in recent guidelines remains adequate in our setting.

**Author contributions**

Conception and design: J. Sellarès-Nadal, J Burgos, V. Falcó; Analysis and interpretation of the data: J. Sellarès-Nadal, R. Sordé, J Burgos, V. Falcó; Drafting of the paper: J. Sellarès-Nadal, J Burgos, V. Falcó; Critical revision for intellectual content; MT. Martin-Gómez, R. Sordé, A. Anton, D. Romero-Herrero, P. Bosch-Nicolau, A. Falcó-Roget, C. Kirkegaard, D. Rodríguez-Pardo, O. Len; Final approval of the version to be published: J. Sellarès-Nadal, J Burgos MT. Martin-Gómez, R. Sordé, A. Anton D. Romero-Herrero, P. Bosch-Nicolau, A. Falcó-Roget, C. Kirkegaard, D. Rodríguez-Pardo, O. Len, V. Falcó.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.

**ORCID**

Júlia Sellarès-Nadal [http://orcid.org/0000-0002-0209-6494](http://orcid.org/0000-0002-0209-6494)
Daniel Romero-Herrero [http://orcid.org/0000-0002-1476-0815](http://orcid.org/0000-0002-1476-0815)
Dolors Rodríguez-Pardo [http://orcid.org/0000-0001-6781-5405](http://orcid.org/0000-0001-6781-5405)

**Data availability statement**

The authors confirm that the data supporting the findings of this study are available within the article.

**References**

[1] Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–160.

[2] Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–427.

[3] Ramírez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812.

[4] Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):E45–E67.

[5] Naucler P, Henriques-Normark B, Hedlund J, et al. Changing epidemiology of community-acquired pneumonia: nationwide register-based study in Sweden. J Intern Med. 2019;286(6):689–701.

[6] Katsurada N, Suzki M, Aoshima M, et al. The impact of virus infections on pneumonia mortality is complex in adults: a prospective multicentre observational study. BMC Infect Dis. 2017;17(1):755.

[7] Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202–209.

[8] Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016;25(140):178–188.

[9] Shoar S, Mushel DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020;12(1):11.

[10] Healthy People 2020. United States Department of Human and Health Services. IID-12.12. Increase the percentage of noninstitutionalized adults aged 18 and older who are vaccinated annually against seasonal influenza. n.d. [cited 2021 Dec 17]. www.healthypeople.gov/node/6360/data_details.

[11] Castillo J, Godoy P, Domínguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis. 2013;57(2):167–175.

[12] Simonetti AF, Garcia-Vidal C, Viasus D, et al. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect. 2016;22(6):567.e1–567.e7.

[13] Murray PR, Washington JA. Microscopic and bacteriological analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339–344.

[14] Self WH, Wunderink RG, Williams DJ, et al. *Staphylococcus aureus* community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016;63(3):300–309.

[15] Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54(8):1126–1133.

[16] Burgos J, Falcó V, Borrego A, et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect. 2013;19(4):385–391.

[17] Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155–163.

[18] Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent
pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48(1):57–64.

[19] Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–366.

[20] Grijalva CG, Nuorti JP, Zhu Y, et al. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010;50(6):805–813.

[21] Burgos J, Lujan M, Falcó V, et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis. 2011;53(3):254–261.

[22] Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? Pulmonology. 2020;26(3):123–129.

[23] Gharbi M, Drysdale JH, Lishman H, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ. 2019;364:i525–12.

[24] Switzer C, Babiuk L, Loeb M.Determining optimal community protection strategies for the influenza vaccine. Expert Rev Vaccines. 2019;18(8):755–764.

[25] Arriola C, Garg S, Anderson EJ, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. Clin Infect Dis. 2017;65(8):1289–1297.

[26] Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629.

[27] Rawson TM, Zhu N, Ranganathan N, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing timothy. Clin Infect Dis. 2020;71:2459–2468.